A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Participants

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: JNJ-39439335 10 mg; Drug: JNJ-39439335 25 mg; Drug: JNJ-39439335 50 mg; Drug: Placebo

• Registration Number: NCT01631487
• Lead Sponsor: Janssen Research & Development, LLC

Brief Summary

The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics of JNJ-39439335 in healthy Japanese and Caucasian adult male participants in Part 1, and in healthy Japanese adult male participants in Part 2.

Detailed Description

This is a double-blind (neither physician nor participant knows the treatment that the participant receives), randomized (the study drug is assigned by chance), placebo-controlled study (placebo is an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial). The study consists of 2 Parts. In Part 1, three groups of healthy Japanese men and 3 groups of healthy Caucasian men will receive a single oral dose of JNJ-39439335 or placebo on Day 1. Each group will include 8 participants. The study duration of Part 1 for each participant is approximately 8 weeks: screening phase of up to 28 days prior to dose, treatment phase of 14 days, and a follow-up phase of 14 to16 days. In Part 2, three groups of healthy Japanese men will receive once-daily doses of either JNJ-39439335 or placebo for 21 days. Each group will include 12 participants. The study duration of Part 2 for each participant is approximately 11 weeks: screening phase of up to 28 days prior to dose, treatment phase of 21 days, and a follow-up phase of approximately 28 days. During the treatment phases, the participants will remain in the study unit. Blood samples and urine will be collected for drug concentration measurements and laboratory safety assessments.

Study Timeline

• Study First Submitted: 2012-06-27
• Study First Submitted QC: 2012-06-27
• Study First Posted: 2012-06-29
• Study Start: 2012-07
• Primary Completion: 2013-03
• Study Completion: 2013-03
• Status Verified: 2013-06
• Last Update Submitted: 2013-06-24
• Last Update Posted: 2013-06-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 86

Inclusion Criteria

• Japanese or Caucasian participants
• Nonsmoker
• Body Mass Index (BMI) of 18 to 30 kg/m2, inclusive, and body weight not less than 50 kg
• Healthy on the basis of a physical examination, vital signs, hematology, coagulation, serum chemistry (including liver function tests) and urinalysis
• Willing to adhere to the prohibitions and restrictions specified by the study protocol

Exclusion Criteria

• Oral temperatures > 37.5 Celsius degrees
• Participants who have occupations or hobbies in which they are routinely exposed to situations in which they could sustain thermal burns
• Abnormal electrocardiogram (ECG) results
• Clinically significant abnormal values for hematology, clinical chemistry or urinalysis
• History of or current clinically significant medical illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Japanese Group 1: JNJ-39439335/placebo (Part 2)	JNJ-39439335 10 mg	-
Japanese Group 2: JNJ-39439335/placebo (Part 2)	Placebo	-
Japanese Group 3: JNJ-39439335/placebo (Part 1)	Placebo	-
Japanese Group 2: JNJ-39439335/placebo (Part 2)	JNJ-39439335 25 mg	-
Japanese Group 3: JNJ-39439335/placebo (Part 2)	JNJ-39439335 50 mg	-
Caucasian Group 1: JNJ-39439335/placebo (Part 1)	Placebo	-
Caucasian Group 3: JNJ-39439335/placebo (Part 1)	JNJ-39439335 50 mg	-
Japanese Group 2: JNJ-39439335/placebo (Part 1)	Placebo	-
Caucasian Group 1: JNJ-39439335/placebo (Part 1)	JNJ-39439335 10 mg	-
Caucasian Group 2: JNJ-39439335/placebo (Part 1)	Placebo	-
Japanese Group 3: JNJ-39439335/placebo (Part 2)	Placebo	-
Japanese Group 2: JNJ-39439335/placebo (Part 1)	JNJ-39439335 25 mg	-
Japanese Group 1: JNJ-39439335/placebo (Part 2)	Placebo	-
Japanese Group 1: JNJ-39439335/placebo (Part 1)	JNJ-39439335 10 mg	-
Japanese Group 3: JNJ-39439335/placebo (Part 1)	JNJ-39439335 50 mg	-
Caucasian Group 2: JNJ-39439335/placebo (Part 1)	JNJ-39439335 25 mg	-
Caucasian Group 3: JNJ-39439335/placebo (Part 1)	Placebo	-
Japanese Group 1: JNJ-39439335/placebo (Part 1)	Placebo	-

Primary Outcome Measures

Name	Time	Method
Urine concentrations of JNJ-39439335 (Part 1)	up to 5 days
Plasma concentrations of JNJ-39439335 (Part 1)	up to 14 days
Urine concentrations of JNJ-39439335 (Part 2)	up to 21 days
Plasma concentrations of JNJ-39439335 (Part 2)	up to 21 days

Secondary Outcome Measures

Name	Time	Method
Incidence of Adverse Events (Part 2)	Approximately 11 weeks
Incidence of Adverse Events (Part 1)	Approximately 8 weeks